Scientists Discover How Ketamine Rewires The Aging Brain To Combat Depression

Mapping the Neural Reorganization That Drives Ketamine’s Antidepressant Effects

A new investigation into the neurological impact of ketamine has uncovered distinct, time-dependent patterns of brain activity in older adults suffering from treatment-resistant depression. The findings, published in Translational Psychiatry, offer a clearer look at how the drug alters brain communication and suggest that specific shifts in neural connectivity could serve as biological markers for clinical success.

While ketamine has gained traction as a rapid-acting intervention for severe depression, its application in older populations has remained cautious due to limited data on how the aging brain responds to its unique pharmacological profile. To bridge this gap, researchers at the Experimental Psychopharmacology of Mood and Anxiety Disorders (EPMAD) Lab at Texas A&M University analyzed data from U.S. veterans over the age of 55 to determine how the drug influences brain organization in later life.

Nicholas Murphy, a research associate professor in the Department of Psychiatry and Behavioral Sciences, likens the mechanism of ketamine to removing a dam, which allows long-stagnant neural pathways to reconnect. According to Murphy, the therapeutic value lies not just in the initial jolt of activity, but in how the brain manages this newfound fluidity. “For it to be useful, we need to understand how that water is flowing, and that’s where our current analysis comes in,” he says. “It tells us how the surging of glutamate released by ketamine needs to flow to get a clinical response.”

To capture this complex, multi-layered process, the research team—which included collaborators from Baylor College of Medicine and the University of the Balearic Islands—moved beyond traditional analysis. While many studies focus on isolated signals or paired interactions, Krisha Shah, a research associate at Texas A&M, noted that the brain functions as a highly integrated network. The team employed high-order interaction analysis, an information-theory approach designed to map how data is organized across multiple EEG signals simultaneously.

The results revealed that ketamine does not trigger a uniform state of activity. Instead, the brain undergoes a dynamic transformation, with distinct organizational patterns emerging at the one-hour, 24-hour, and seven-day marks following a single infusion. Crucially, the study found that a higher degree of brain-wide information sharing recorded at the 24-hour mark was directly linked to more significant symptom relief by the seventh day.

This research extends previous work by the EPMAD Lab, which had already established the feasibility and safety of intravenous ketamine for older patients. By identifying these specific temporal markers, the researchers hope to gain a deeper understanding of why clinical outcomes vary among patients.

Beyond the immediate potential for improving care, the findings serve a larger goal: identifying the precise physiological mechanisms behind ketamine’s success. Murphy emphasizes that the ultimate objective is to pinpoint these pathways so that future treatments might replicate the antidepressant effects without the limitations associated with ketamine, such as its abuse potential and psychedelic side effects.

“Most drug studies end at age 65, leaving relatively little research on how ketamine affects the aging brain,” says Murphy, noting that older adults are frequently overlooked in clinical research despite representing a significant portion of the population. By mapping the “physiological roadmap” of the brain after treatment, the team is working toward a more targeted approach to treating depression in an aging demographic.